Daniela Lucía Florez-Restrepo

Daniela Lucía Florez-Restrepo

Auto-generated profile, based on publicly available information

Daniela Lucía Florez-Restrepo

Médico, Corporación Universitaria Remington. Medellín, Colombia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Archivos de Medicina (Manizales)
Verified
Journal Article
Open access
PDF file
SGSalomon Gallego-Quintero
Salomon Gallego-Quintero
APAna María Patiño-Isaza
Ana María Patiño-Isaza
DFDaniela Lucía Florez-Restrepo
Daniela Lucía Florez-Restrepo
DBDione Benjumea-Bedoya
Dione Benjumea-Bedoya
ISIsaura Pilar Sanchez
Isaura Pilar Sanchez
JAJuan Carlos Alzate-Ángel
Juan Carlos Alzate-Ángel
Background: Despite combined antiretroviral therapy effectiveness for the control of HIV infection, 15-30% of these patients develop Immune Reconstitution Inflammatory Syndrome (IRIS), consisting in a clinical worsening at the beginning of combined Antiretroviral Therapy (cART). It is important to know the prevalence and characteristics of people with IRIS to generate prevention strategies. Objective: To describe the prevalence and sociodemographic characteristics of patients with IRIS HIV-related, from a health care facility in Antioquia - Colombia. Methods: In a population of 515 patients that started cART between 2.013-2.018, we developed a cross-sectional study with a simple random sampling of 188 HIV patients. The presence of IRIS was defined according to French criteria or high suspected IRIS in those who had insufficient clinical information and have developed an opportunistic infection (OI) after cART initiation. Results: The prevalence of IRIS was 12,8% (12,5% by French criteria and 87,5% by high suspected IRIS). IRIS patients were 25% women, median age 41,5 years. 87,5% presented OI. From these, the most common was tuberculosis disease (72,7%). Conclusions: In the era of cART, there are still an important number of IRIS cases, which indicates the need to continue implementing preventive and diagnostic protocols and early treatment initiation.